Subscribe to our Newsletters !!
Fermentation is a natural method which is applied
A CO2 incubator is one of the most integral pieces
The human metapneumovirus, more simply referred to
Indegene, a digital-first life sciences commercial
Alembic Pharmaceuticals Limited (Alembic) announce
'Simplicity' seems to be the perfect word to descr
Dear Readers, Welcome to the latest issue of The Magazine
Cipla Limited (BSE: 500087; NSE: CIPLA EQ) referred to as “Cipla” today announced the launch of CipAir®️, a mobile application designed to enable timely and convenient first line of screening for asthma in India. This first-of-its-kind technology is clinically validated through a multi-centric pan-India study. It aims to empower people by helping them understand their likelihood of an asthma diagnosis thereby allowing them to seek timely intervention and management in case of such indications.
According to the Global Burden of Disease report, the total burden of asthma in India is estimated to be 34.3 million. India has three times higher mortality, and more than two times higher disability-adjusted life years compared to the global proportion of asthma burden[1]. This is further exacerbated by deteriorating air quality. Herein, the mobile-based screening will serve as an easily accessible starting point for diagnosis and enable asthmatics or likely candidates to effectively manage their condition in time and lead a normal lifestyle.
Available on Android and to be subsequently rolled out on iOS devices, CipAir®️ is a free tool accessible through the Breathefree mobile application, Cipla’s existing patient support ecosystem for respiratory care. Through its proprietary algorithm and software, it transforms one’s mobile phone into an asthma screening device using detailed acoustic signature analysis coupled with artificial neural network science. When performed in quiet surroundings as directed by the tool, in less than a minute, through three guided exhalations into the handset, the tool produces a personalised result that indicates the presence, absence or likely future onset of asthma, and guides people to appropriate action basis the findings. Users are further equipped with access to vital knowledge resources pertaining to lung health and qualified experts via Cipla’s extensive Breathefree platform.
To cascade awareness and usage of this cutting-edge offering, CipAir®️ will be promoted through Cipla’s Breathefree platform and a solid network of on-ground field force. The feature will continue to see further enhancements that will further strengthen the asthma management ecosystem in the country.
Speaking about this latest addition to Cipla’s innovation portfolio, Mr. Umang Vohra, Managing Director & Global CEO of Cipla said, “At Cipla, our approach to healthcare is deeply rooted in innovation. By leveraging the power of next-gen technologies, we are developing solutions that are fundamentally transforming patient care and enabling better diagnostic, treatment, and management outcomes. Patient-centricity is at the heart of what we do, and CipAir®️’s AI-led technology is yet another step forward in making personalised healthcare accessible and user-friendly, thereby empowering them to live fuller lives.”
Commenting on this latest technology, Mr. Achin Gupta, CEO, One India Business, Cipla, said, “CipAir®️ is a powerful clinically validated tool that puts health in the hands of patients and enables timely intervention against asthma so that they don’t have to compromise on their quality of life. As lung leaders, it is our firm resolve to help India tackle its growing asthma burden and breathe free through such cutting-edge solutions that strengthen the asthma care ecosystem.”
